The Prostate Core Mitomic Test (PCMTTM) provides an easy way to confirm prostate biopsy results without additional procedures. It examines mitochondrial DNA from biopsy tissue to identify cellular changes associated with prostate cancer. A negative PCMT result confirms a negative biopsy, while a positive result means the patient is at high risk for undiagnosed cancer. Insurance often covers the PCMT, and the results are available when the original biopsy is evaluated to help guide treatment decisions.
Improving Management of Non-Metastatic Castration-Resistant Prostate Cancer (...Carevive
NOT FOR CME - FOR REFERENCE ONLY
In 2018, there will be an estimated 164,690 new cases of prostate cancer (PC) in the U.S. and approximately 29,430 patients will die of the disease, making it the third-leading cause of cancer death in men (American Cancer Society [ACS], 2018). The majority of men with PC are treated with curative intent (i.e., with radical prostatectomy or radiation therapy) with good outcomes, but a fraction of men with locoregional PC will develop progressive disease. Men who have initial PSA/biochemical recurrence after curative treatment are a heterogeneous group of individuals with good overall prognosis, including a median metastasis-free survival (MFS) >8 years and a median overall survival (OS) of >23 years (Rozet et al., 2016).
Approximately 10%-20% of prostate cancer patients develop castration-resistant PC (CRPC) within approximately 5 years of follow-up. Decisions about clinical management (i.e., when to start treatment) are challenging because it is unclear which patients will have shorter versus longer survival, and metastatic disease is not always reliably detected with imaging (Rozet et al., 2016).
Multiple new targeted agents, including immunotherapy, second-generation hormone therapy, and androgen biosynthesis inhibitors have been recently approved. Two recently published studies (PROSPER and SPARTAN) have changed the standard of care for patients with nmCRPC.
Don’t miss our upcoming webinars: Subscribe today!
In this webinar:
The basics of advanced prostate cancer, what it means to have non-metastatic castration resistant prostate cancer, the new treatment options now available for this disease space, and the prognosis for patients in this state of disease.
Presented by Dr. Robert Hamilton, urologic oncologist at Princess Margaret Cancer Centre and Associate Professor in the Department of Surgery (Urology) at the University of Toronto, this webinar will provide an overview of this subset of prostate cancer.
Dr. Hamilton’s clinical and research interests are in prostate cancer and testicular cancer. Dr. Hamilton trained at the University of Toronto and has completed a Masters of Public Health at The University of North Carolina at Chapel Hill, and a research fellowship at Duke University. He has also completed a fellowship at Memorial Sloan-Kettering Cancer Centre.
View the video:
https://youtu.be/wE3EVJm5Oo4
To learn more about CCSN, visit us at survivornet.ca
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Arab Health 2011: PET/CT in Chest ImagingTom Heston MD
Thomas F Heston, MD, FACNM, FASNC discusses molecular imaging uses in chest diseases, primarily oncology, lung cancer. Discussed are the uses of 18F-FDG and 18F-NaF.
Improving Management of Non-Metastatic Castration-Resistant Prostate Cancer (...Carevive
NOT FOR CME - FOR REFERENCE ONLY
In 2018, there will be an estimated 164,690 new cases of prostate cancer (PC) in the U.S. and approximately 29,430 patients will die of the disease, making it the third-leading cause of cancer death in men (American Cancer Society [ACS], 2018). The majority of men with PC are treated with curative intent (i.e., with radical prostatectomy or radiation therapy) with good outcomes, but a fraction of men with locoregional PC will develop progressive disease. Men who have initial PSA/biochemical recurrence after curative treatment are a heterogeneous group of individuals with good overall prognosis, including a median metastasis-free survival (MFS) >8 years and a median overall survival (OS) of >23 years (Rozet et al., 2016).
Approximately 10%-20% of prostate cancer patients develop castration-resistant PC (CRPC) within approximately 5 years of follow-up. Decisions about clinical management (i.e., when to start treatment) are challenging because it is unclear which patients will have shorter versus longer survival, and metastatic disease is not always reliably detected with imaging (Rozet et al., 2016).
Multiple new targeted agents, including immunotherapy, second-generation hormone therapy, and androgen biosynthesis inhibitors have been recently approved. Two recently published studies (PROSPER and SPARTAN) have changed the standard of care for patients with nmCRPC.
Don’t miss our upcoming webinars: Subscribe today!
In this webinar:
The basics of advanced prostate cancer, what it means to have non-metastatic castration resistant prostate cancer, the new treatment options now available for this disease space, and the prognosis for patients in this state of disease.
Presented by Dr. Robert Hamilton, urologic oncologist at Princess Margaret Cancer Centre and Associate Professor in the Department of Surgery (Urology) at the University of Toronto, this webinar will provide an overview of this subset of prostate cancer.
Dr. Hamilton’s clinical and research interests are in prostate cancer and testicular cancer. Dr. Hamilton trained at the University of Toronto and has completed a Masters of Public Health at The University of North Carolina at Chapel Hill, and a research fellowship at Duke University. He has also completed a fellowship at Memorial Sloan-Kettering Cancer Centre.
View the video:
https://youtu.be/wE3EVJm5Oo4
To learn more about CCSN, visit us at survivornet.ca
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Arab Health 2011: PET/CT in Chest ImagingTom Heston MD
Thomas F Heston, MD, FACNM, FASNC discusses molecular imaging uses in chest diseases, primarily oncology, lung cancer. Discussed are the uses of 18F-FDG and 18F-NaF.
Presentation is highlighting the integration of different modalities in the management of locally advanced and metastatic prostate cancer pointing to the proven values of adding chemotherapy. A special note has been made to oligometastatic disease.
High Risk disease is defined as “apparent localized cancer that has a high propensity of micro-metastatic disease” (cancer that is not visible on convention radiography, such as bone and CT scans). These cancers, once removed via radiation or surgery, are likely to "return," but in fact, they were never removed in the first place because the cancer cells were outside the treated region.
Therefore, successful eradication of high risk disease requires both aggressive local control and systemic treatment with androgen deprivation therapy and extended field radiation. This lecture will review the most up-to-date data on dose-intensity radiation therapy, pelvic radiation, surgery with adjuvant radiation, and adjuvant hormone therapy. Finally, data on experimental chemotherapy and abiraterone (Zytiga) will be presented.
Oncology Big Data: A Mirage or Oasis of Clinical Value? Michael Peters
The title of the presentation, Oncology Big Data: A Mirage or Oasis of Clinical Value, reflects what I believe the field of Oncology is challenged with on a growing basis, from a clinical and business side perspective.
Presented by the Johns Hopkins University School of Medicine and
produced in collaboration with the Institute for Medical Education & Research (IMER).
Review a downloadable slide deck by, covering the most clinically relevant new data reported from Expert Video Viewpoints on Castration-Resistant Prostate Cancer: Care Across the Continuum by:
Emmanuel Antonarakis, MBBCh
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital
Leonard G. Gomella, MD, FACS
Thomas Jefferson University
Jefferson Kimmel Cancer Center
A. Oliver Sartor, MD
Tulane University School of Medicine
Target Audience
Medical oncologists, urologists, radiation oncologists, and other healthcare professionals involved in the treatment of patients with castration-resistant prostate cancer (CRPC). There are no prerequisites.
Activity Overview
In this video, a panel of expert thought leaders will discuss the optimal management and emerging agents across the CRPC treatment continuum. Topics will include identification and initial treatment of CRPC, metastatic CRPC progression, future novel treatment for CRPC patients, and expert perspectives on case examples to decipher optimal treatment of CRPC.
Slide Deck Disclaimer
This slide deck in its original and unaltered format is for educational purposes and is current as of December 2011. All materials contained herein reflect the views of the faculty, and not those of IMER, the CME provider, or the commercial supporter. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. Readers should not rely on this information as a substitute for professional medical advice, diagnosis, or treatment. The use of any information provided is solely at your own risk, and readers should verify the prescribing information and all data before treating patients or employing any therapeutic products described in this educational activity.
Usage Rights
This slide deck is provided for educational purposes and individual slides may be used for personal, non-commercial presentations only if the content and references remain unchanged. No part of this slide deck may be published in print or electronically as a promotional or certified educational activity without prior written permission from IMER. Additional terms may apply. See Terms of Service on IMERonline.com for details.
EIS Technology: bioimpedance chronoamperometry in adjunct to screen the prost...ES-Teck India
Through the 6 tactile electrodes, a weak DC current is sending alternatively between 2 electrodes with a sequence and the EIS system is recording the electrical conductance of 11 pathways of the human body.
Presentation is highlighting the integration of different modalities in the management of locally advanced and metastatic prostate cancer pointing to the proven values of adding chemotherapy. A special note has been made to oligometastatic disease.
High Risk disease is defined as “apparent localized cancer that has a high propensity of micro-metastatic disease” (cancer that is not visible on convention radiography, such as bone and CT scans). These cancers, once removed via radiation or surgery, are likely to "return," but in fact, they were never removed in the first place because the cancer cells were outside the treated region.
Therefore, successful eradication of high risk disease requires both aggressive local control and systemic treatment with androgen deprivation therapy and extended field radiation. This lecture will review the most up-to-date data on dose-intensity radiation therapy, pelvic radiation, surgery with adjuvant radiation, and adjuvant hormone therapy. Finally, data on experimental chemotherapy and abiraterone (Zytiga) will be presented.
Oncology Big Data: A Mirage or Oasis of Clinical Value? Michael Peters
The title of the presentation, Oncology Big Data: A Mirage or Oasis of Clinical Value, reflects what I believe the field of Oncology is challenged with on a growing basis, from a clinical and business side perspective.
Presented by the Johns Hopkins University School of Medicine and
produced in collaboration with the Institute for Medical Education & Research (IMER).
Review a downloadable slide deck by, covering the most clinically relevant new data reported from Expert Video Viewpoints on Castration-Resistant Prostate Cancer: Care Across the Continuum by:
Emmanuel Antonarakis, MBBCh
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital
Leonard G. Gomella, MD, FACS
Thomas Jefferson University
Jefferson Kimmel Cancer Center
A. Oliver Sartor, MD
Tulane University School of Medicine
Target Audience
Medical oncologists, urologists, radiation oncologists, and other healthcare professionals involved in the treatment of patients with castration-resistant prostate cancer (CRPC). There are no prerequisites.
Activity Overview
In this video, a panel of expert thought leaders will discuss the optimal management and emerging agents across the CRPC treatment continuum. Topics will include identification and initial treatment of CRPC, metastatic CRPC progression, future novel treatment for CRPC patients, and expert perspectives on case examples to decipher optimal treatment of CRPC.
Slide Deck Disclaimer
This slide deck in its original and unaltered format is for educational purposes and is current as of December 2011. All materials contained herein reflect the views of the faculty, and not those of IMER, the CME provider, or the commercial supporter. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. Readers should not rely on this information as a substitute for professional medical advice, diagnosis, or treatment. The use of any information provided is solely at your own risk, and readers should verify the prescribing information and all data before treating patients or employing any therapeutic products described in this educational activity.
Usage Rights
This slide deck is provided for educational purposes and individual slides may be used for personal, non-commercial presentations only if the content and references remain unchanged. No part of this slide deck may be published in print or electronically as a promotional or certified educational activity without prior written permission from IMER. Additional terms may apply. See Terms of Service on IMERonline.com for details.
EIS Technology: bioimpedance chronoamperometry in adjunct to screen the prost...ES-Teck India
Through the 6 tactile electrodes, a weak DC current is sending alternatively between 2 electrodes with a sequence and the EIS system is recording the electrical conductance of 11 pathways of the human body.
What is biomarker?
What is the purpose of biomarker
Processes of biomarker development?
Types of Biomarkers
What is biomarker testing for cancer treatment?
Uses of Biomarkers in Cancer Medicine
Uses of Biomarkers in Cancer Drug Discovery
introduction
What is biomarker?
What is the purpose of biomarker
Processes of biomarker development?
Types of Biomarkers
What is biomarker testing for cancer treatment?
Uses of Biomarkers in Cancer Medicine
Uses of Biomarkers in Cancer Drug Discovery
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
2. Why should I believe What do the results mean? How do I pay for the Prostate
the results of the Prostate Core Mitomic Test?
Negative Positive
Core Mitomic Test? If you have Medicare, you are responsible for any
applicable deductible and co-payment as required
Unlike the biopsy, which only examines tissue from
by federal insurance regulations. Co-pays are
specific areas of the prostate, the Prostate Core
20-percent of the Medicare allowable.
Mitomic Test can identify abnormalities in cells that
The Prostate are near tumors, not just in the tumors themselves.
The Prostate Core Mitomic Test works by recognizing
A negative PCMT result A positive PCMT result For commercial insurance, Mitomics accepts the
insurer’s contracted allowed amount for the Prostate
Core Mitomic Test
confirms the negative means you are at a high
changes in your mitochondrial DNA. Mitochondria are result of your biopsy. With risk for undiagnosed Core Mitomic Test as payment in full. Please note that
structures within a cell that produce energy for the cell. a high degree of certainty, prostate cancer. Your Mitomics is not currently a participating provider with
(PCMT™) examines Mitochondrial DNA is highly susceptible to damage. PCMT identifies that you doctor can use this
all insurers. If your insurance company denies coverage
do not currently have information to tailor
The Prostate Core Mitomic Test identifies the damage because Mitomics is out of network, Mitomics will
prostate cancer. Because a treatment based on
tissue taken from to mitochondrial DNA caused by cellular changes
associated with prostate cancer development.
an additional biopsy is not your personal situation. work with you directly to appeal the claim. You will be
responsible for your normal co-pay, deductibles, and/or
your biopsy. You
needed, you can avoid By knowing your risk
extra pain and anxiety – earlier, you can make co-insurance requirements as identified by your plan.
The Prostate Core Mitomic Test is a highly sensitive and have peace of mind more informed decisions
do not need to
test that can pick out this damage in normal cells that you are prostate concerning your health. The explanation of benefits (EOB) is not a bill. Do not
that are adjacent to tumors. As you can see in the cancer free today. make a payment to Mitomics upon receipt of an EOB.
have any additional
diagram, the cancerous tumor can be quite small, You will be billed in accordance to the billing policy
and the biopsy cores may not come in contact with noted above – not the amounts stated on the EOB.
When will I receive
surgeries or even
the tumor. However, the Prostate Core Mitomic Test
If you receive insurance proceeds directly, these
can identify the presence of the tumor because the
the results? proceeds must be forwarded to Mitomics to settle
a doctor’s visit.
mitochondrial DNA in the tissue throughout the prostate
could indicate changes at the cellular level. Your doctor will order the Prostate Core Mitomic the billed amount. Mitomics does not use a collection
Test when your biopsy is submitted for evaluation. agency; however, in this circumstance, you will
A special lab processes your biopsy tissue, and receive a letter from Mitomics asking that you forward
BLADDER the results will be sent to your doctor. Your doctor proceeds to Mitomics.
will then contact you to discuss the results.
TUMOR
PROSTATE
If you have any questions concerning billing, health care
FIELD
EFFECT coverage, or payment for the Prostate Core Mitomic Test,
please contact:
If you have any questions about BIOPSY CORE
GGB Medical Management Services, Inc.
the Prostate Core Mitomic Test TUMOR
PO Box 2311
or your biopsy results, talk to Chatsworth, CA 91313-2311
your doctor. www.ggbmedical.com 818.718.9519 Spanish
URETHRA
800.718.9505 Toll-free 818.718.9507 Fax